Key Takeaway
Clinical evidence review of semaglutide's effects on blood pressure. Trial data from SUSTAIN, STEP, and SELECT programs with specific BP reduction findings.
Executive Summary
Semaglutide, a GLP-1 receptor agonist available as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management), has consistently demonstrated clinically meaningful reductions in systolic blood pressure across multiple phase 3 clinical trial programs. Systolic blood pressure reductions of 3 to 7 mmHg have been observed across the SUSTAIN, STEP, and SELECT trials, with effects that appear to be driven by a combination of weight loss, direct vascular mechanisms, and natriuretic effects. This article examines the specific trial data supporting semaglutide's blood pressure-lowering properties.
Clinical Evidence: Blood Pressure Data From Major Trials
SUSTAIN Program (Semaglutide 0.5 mg and 1.0 mg in Type 2 Diabetes)
Blood pressure was measured as a secondary or exploratory endpoint across the SUSTAIN trials. The results consistently showed systolic blood pressure reductions with semaglutide: For a complete cost breakdown, see our compare semaglutide prices.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
- SUSTAIN 1 (monotherapy): Semaglutide 1.0 mg reduced systolic BP by 3.4 mmHg versus an increase of 1.4 mmHg with placebo over 30 weeks
- SUSTAIN 2 (vs. sitagliptin): Semaglutide 1.0 mg reduced systolic BP by 5.1 mmHg versus 2.3 mmHg with sitagliptin over 56 weeks
- SUSTAIN 6[1] (cardiovascular outcomes): Over the 2.1-year study period, semaglutide 1.0 mg produced a sustained systolic BP reduction of approximately 2.6 mmHg relative to placebo
- SUSTAIN 7 (vs. dulaglutide): Semaglutide 1.0 mg reduced systolic BP by 5.4 mmHg versus 2.8 mmHg with dulaglutide 1.5 mg over 40 weeks
A pooled analysis of the SUSTAIN program found that semaglutide 1.0 mg reduced systolic blood pressure by a weighted mean of approximately 4.7 mmHg, with the magnitude of reduction correlating with, but not fully explained by, the degree of weight loss .
STEP Program (Semaglutide 2.4 mg for Weight Management)
The STEP trials used the higher 2.4 mg dose of semaglutide and enrolled populations with obesity, with or without type 2 diabetes:
- STEP 1[2]: In adults with obesity (without diabetes), semaglutide 2.4 mg reduced systolic BP by 6.2 mmHg versus 1.1 mmHg with placebo over 68 weeks. Diastolic BP decreased by 2.8 mmHg versus 0.4 mmHg
- STEP 2[3]: In adults with obesity and type 2 diabetes, semaglutide 2.4 mg reduced systolic BP by 3.9 mmHg versus 0.5 mmHg with placebo over 68 weeks
- STEP 3[4]: When combined with intensive behavioral therapy, semaglutide 2.4 mg reduced systolic BP by 5.6 mmHg versus 1.6 mmHg with placebo
- STEP 4[5] (withdrawal study): This trial randomized patients who had been on semaglutide 2.4 mg for 20 weeks to either continue or switch to placebo. Those who continued semaglutide maintained a 5.3 mmHg systolic BP reduction, while those switched to placebo saw blood pressure rise by 4.4 mmHg over the subsequent 48 weeks, demonstrating that the blood pressure benefit is treatment-dependent
SELECT Trial[6] (Cardiovascular Outcomes in Obesity Without Diabetes)
The SELECT trial enrolled over 17,600 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced systolic BP by approximately 3.3 mmHg relative to placebo over the course of the trial. This blood pressure reduction occurred in a population already receiving guideline-directed antihypertensive therapy, suggesting that semaglutide provides additive blood pressure lowering on top of standard medications .
FLOW Trial (Renal Outcomes)
In the FLOW trial (semaglutide 1.0 mg in patients with type 2 diabetes and CKD), semaglutide reduced systolic BP by approximately 3.0 mmHg. This is notable because blood pressure control is critical in preserving kidney function, and the BP reduction may have contributed to the observed 24% reduction in the kidney composite endpoint .
Ambulatory Blood Pressure Monitoring Data
Office blood pressure measurements can be affected by white-coat effects and measurement variability. A substudy using 24-hour ambulatory blood pressure monitoring (ABPM) in patients receiving semaglutide demonstrated that the blood pressure reductions observed in office readings are confirmed and consistent across 24 hours, including during nighttime hours. This suggests a sustained hemodynamic effect rather than a transient or measurement-related artifact .
Subgroup Analyses by Baseline Blood Pressure
Post-hoc analyses from the SUSTAIN and STEP programs have examined whether the blood pressure effect differs by baseline BP. Patients with higher baseline systolic blood pressure (above 130 mmHg) tend to experience larger absolute reductions (5 to 8 mmHg) compared to those with normal baseline BP (2 to 3 mmHg). semaglutide doesn't cause clinically significant hypotension in normotensive patients .
Mechanism: How Semaglutide Lowers Blood Pressure
The blood pressure-lowering effect of semaglutide is multifactorial. Research has identified several contributing mechanisms:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Weight loss-mediated effects: Weight loss is the most obvious contributor. Each kilogram of weight loss is generally associated with approximately 1 mmHg reduction in systolic blood pressure . Given that semaglutide produces 5 to 15 kg of weight loss in most patients, this accounts for a significant portion of the observed BP reduction. But mediation analyses from the STEP trials suggest that weight loss explains only about 40 to 50% of the total blood pressure effect, indicating that weight-independent mechanisms are also at play .
Natriuretic effect: GLP-1 receptors are expressed in the kidneys, and GLP-1 agonists promote sodium excretion (natriuresis). In human studies, semaglutide has been shown to increase urinary sodium excretion, which lowers blood volume and consequently blood pressure .
Endothelial function: Human studies have demonstrated improvements in flow-mediated dilation (a measure of endothelial function) with GLP-1 agonist therapy. Better endothelial function means blood vessels relax more effectively, reducing vascular resistance .
Sympathetic nervous system modulation: Preclinical evidence (primarily from animal models) suggests that GLP-1 agonists may reduce sympathetic nervous system activity, which could lower heart rate variability and vascular tone. Human data on this mechanism are more limited and require further study .
Reduced arterial stiffness: Pulse wave velocity studies in human subjects have shown reductions in arterial stiffness with semaglutide treatment, independent of blood pressure changes. Reduced arterial stiffness lowers central aortic pressure, which is a stronger predictor of cardiovascular events than peripheral blood pressure .
Safety Profile
Blood Pressure-Specific Safety Considerations
Semaglutide's blood pressure-lowering effect is generally beneficial, but there are specific considerations:
- Orthostatic hypotension: Rarely reported in clinical trials. Patients who are already on multiple antihypertensive medications and experience significant weight loss may need their blood pressure medications adjusted downward
- Heart rate: Semaglutide consistently increases resting heart rate by 2 to 4 beats per minute across trials. This effect has been observed with the entire GLP-1 agonist class and doesn't appear to be associated with adverse cardiovascular outcomes based on the SELECT and SUSTAIN-6 trial results
- Dehydration risk: GI side effects (nausea, vomiting, diarrhea) can lead to dehydration, which may cause blood pressure drops in some patients. Adequate fluid intake is important, especially during the initial weeks of therapy and dose escalation
General Safety Profile
The overall safety profile of semaglutide has been extensively characterized across trials enrolling over 20,000 participants. Common side effects include nausea (15-25%), vomiting (5-10%), diarrhea (8-15%), and constipation (5-10%), which are typically transient and manageable with gradual dose escalation. Serious but rare risks include pancreatitis, gallbladder events, and the thyroid C-cell tumor concern based on rodent (not human) data .
Practical Implications
The clinical evidence for semaglutide's blood pressure effects carries several practical implications:
- Antihypertensive medication adjustment: Patients starting semaglutide who are already on blood pressure medications should have their BP monitored regularly. As weight loss progresses and semaglutide's vascular effects develop, some patients may require dose reductions in their antihypertensive medications to avoid hypotension
- Cardiovascular risk reduction: A sustained 5 mmHg reduction in systolic blood pressure is associated with approximately a 10% reduction in major cardiovascular events based on large meta-analyses of antihypertensive trials . This suggests that semaglutide's BP-lowering effect contributes meaningfully to its observed cardiovascular benefits in SELECT and SUSTAIN-6
- Treatment-dependent effect: The STEP 4 withdrawal data clearly demonstrate that BP reductions reverse upon discontinuation. This should be factored into discussions about long-term treatment planning
- Additive benefit: The SELECT trial showed that semaglutide lowers BP even in patients already taking antihypertensive medications, suggesting it can provide benefit as part of a thorough cardiovascular risk management strategy
Frequently Asked Questions
How much does semaglutide lower blood pressure?
Across clinical trials, semaglutide reduces systolic blood pressure by approximately 3 to 7 mmHg, depending on the dose and population studied. The 2.4 mg dose (Wegovy) tends to produce larger reductions than the 1.0 mg dose (Ozempic), likely because of greater associated weight loss. Patients with higher baseline blood pressure tend to see larger reductions .
Is semaglutide approved as a blood pressure medication?
No. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Its blood pressure-lowering effect is an observed benefit that occurs alongside its primary glucose-lowering and weight-loss effects. It isn't a substitute for dedicated antihypertensive medications in patients with hypertension .
Does the blood pressure effect last as long as I take the medication?
Yes. The STEP 4 and SUSTAIN-6 trials both show that blood pressure reductions are maintained for as long as treatment continues. When semaglutide is discontinued, blood pressure tends to rise back toward pre-treatment levels within weeks to months .
Should my blood pressure medications be adjusted if I start semaglutide?
Possibly. If you experience significant weight loss and blood pressure reductions, your provider may need to lower the dose of your existing blood pressure medications to prevent your BP from dropping too low. This is especially important if you're taking multiple antihypertensive agents. Don't adjust your medications on your own without consulting your provider .
Does semaglutide affect diastolic blood pressure too?
Yes, but the effect on diastolic blood pressure is smaller and less consistent than the systolic effect. In the STEP 1 trial, diastolic BP decreased by 2.8 mmHg with semaglutide 2.4 mg versus 0.4 mmHg with placebo. In the SUSTAIN trials, diastolic reductions ranged from 0.5 to 2.0 mmHg .
Medical References
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
If you're interested in how semaglutide might benefit your blood pressure alongside diabetes or weight management, our physician-supervised telehealth platform can help. Connect with a licensed provider who specializes in GLP-1 and peptide therapy for a personalized evaluation of your cardiovascular and metabolic health. Start your consultation today.